show the principal characteristics of the studies included in the analyses. A complete list of referenced studies is given in the Appendix.
Cancer of the ovary is the fifth most common neoplasm among women (American Cancer Society, 1986) . Approximately 70% of patients present with advanced stage disease at diagnosis and 85% of them eventually die as a result of their disease (Richardson et al., 1985) . Long term survival is disappointingly low. Partially for this reason, a plethora of drugs, combinations and schedules are used in attempts to derive the most benefit from chemotherapy with acceptable toxicity. It is surprising, therefore, that, despite the abundant experimental and retrospective clinical evidence supporting the importance of drug dosage and time relationships (Bonadonna & Valgussa, 1981; De Vita, 1986) , no randomised trials specifically designed to answer the dose intensity question in ovarian cancer have yet been conducted. Dose intensity, defined as the amount of drug delivered per unit of time and usually standardised to body area surface as mgm2wk (Green et al., 1980) , correlates with outcome of chemotherapy in many cancers and in ovarian cancer there is some retrospective evidence that it could be important (Levin & Hryniuk, 1987a,b) . These retrospective analyses have, however, been subject to criticism on methodologic grounds (Henderson et al., 1988) . We felt that the methodology of meta-analyses of randomised clinical trials could be useful in attempting to get more reliable information from retrospective studies (L'Abbe et al., 1987) . Therefore, given the importance of the dose intensity issue and the possibility of utilising retrospective data in a more methodologically sound way, we undertook an analysis of the results of randomised clinical trials in ovarian cancer to determine if a relationship between dose intensity and outcome exists in advanced ovarian cancer. We attempted to determine which commonly used agents alone or in combination show the best dose intensity outcome relationships. 
Statistical analysis
For each drug, raw intensity was defined as the planned rate of delivery expressed on a mg m2 wk basis. The relative dose intensity of a particular drug was then expressed using the 'equalised standard method' (Levin & Hryniuk, 1987a) as the raw intensity divided by the dose intensity of that same drug which produces a 40% objective response rate in previously untreated patients. Table II shows the reference equiresponse dose intensities for each drug analysed. The total dose intensity for a particular regimen is the sum of the relative dose intensities for each constituent drug of the regimen. The analyses utilised two different models. The first is Yij = a, + P Iij + eij where yij is the observed log odds of objective response or log median survival and Iij is the total dose intensity of the j'th treatment arm of the i'th study. The term oi represents the fixed effect of the i'th study and eij accounts for random error. The unknown regression coefficient P estimates the magnitude of the relationship between dose intensity and outcome. The inclusion of a separate fixed effect for each study provides for systematic differences in response or survival among the studies due to patient selection, response assessment, etc. Therefore, in estimating dose intensity effects rate for arm j of the study i. For the analysis of the relationship between log median survival and dose intensity, the weights were wij = the number of deaths in arm j of the study i. These weights insure that study arms with more information contribute more to the regressions.
For both models, partial regression plots (Velleman & Welsch, 1981) were used to display the data. For the first model, these plots are of the outcomes adjusted for study effects, (yij-yi) vs the total dose intensity adjusted for study effects, (Iij-Ii), where yi and Ii are weighted average outcome and weighted average dose intensity respectively for the i'th study. The slope of a weighted linear regression fit to this data is the regression coefficient P relating dose intensity to outcome. For the second model, plots can be obtained for agent X as follows: First, the outcome is regressed on all the other agents and the study effects (using the weights). Secondly, the total dose intensity is regressed on all the other agents and study effects (using the weights). Then the residuals from the first regression are plotted against the residuals from the second regression. The slope of a weighted linear regression fit to this data is the partial regression coefficient P1 relating dose intensity of agent X to outcome.
In all plots, bubbles with area proportional to the weights are used as a plotting symbol so that one can see which treatment arms are contributing more to the estimated regression coefficients. Additionally, in all plots the axes have been relabeled for ease of interpretation.
The null hypothesis that the inclusion of the study effects (os's) was unnecessary in the modeling was tested with an F test.
Results
Examination of the relationship between response and total dose intensity was performed using the regression model defined in the Methods section. The estimate of the regression coefficient P relating log odds of response total dose intensity was 0.64 (SE = 0.18, P = 0.0008). To put this regression coefficient on a more interpretable scale, Table IV displays the predicted response rate for a 1.0 unit increase in dose intensity given certain baseline response rates. For example, an increase in cisplatin dose of 1O mg m2 wk and cyclophosphamide dose of 175 mg m2 wk would correspond to a 1.0 ( = 0.5 + 0.5) increase in dose intensity as defined in Table II . If the baseline response rate was 40%, then this increase would lead to a response rate of 56% (90% confidence interval = 48%-63%). We see in Table IV that for the baseline rates considered that an increase in 1 unit of dose intensity yields predicted increases in response rates of 12% to 16%.
When analysing the median survival and total dose intensity relationship, the estimate of P was 0.14 (SE = 0.06, survival for a 1.0 unit increase in dose intensity. The increase is in the range of 2 to 4 months. The partial regression plots for response rates and median survival are given in Figures 1 and 2 . The weaker relationship between survival and dose intensity is reflected in the larger amount of scatter in Figure 2 , although both figures have considerable scatter. Table III presents the results of using the second model for examining the effects of individual drugs. For response, there is a positive relationship between dose intensity for platinum (P= 0.0003), doxorubicin (P= 0.017), and cyclophosphamide (P = 0.068). Table VI displays the predicted response rates for an increase in 1.0 unit of dose intensity for these agents individually, or in combination (1/3 unit increase for each drug). For an increase in 1.0 unit of dose intensity, cyclophosphamide is relatively less effective than the platinum compounds or doxorubicin. This can also be seen in the partial residual plots (Figure 3) where there the smaller dose/response association can be seen for cyclophosphamide.
Although no association was found for hexamethylmelamine or the antimetabolites, notice that the standard errors for these agents were considerably larger than for the other agents. This suggests that there was insufficient studies with high enough doses of these agents to be able to estimate the association well. The correct interpretation of these results is not that there is no dose-response for these agents, but instead that the data was insufficient to make a statement concerning the dose response.
For the relationship between dose intensity and median survival, there was a significant and positive association for platinum (P = 0.0092) and doxorubicin (P = 0.0083). The association for cyclophosphamide was paradoxically negative, although not statistically significant. The predicted effects on median survival for a 1.0 unit increase in dose intensity are given in Table VII . The partial residual plots are given in Figure 4 .
When the analyses were repeated restricted to those 25 studies that had both response and survival data available, the results were very similar to those reported above with one exception. The regression coefficient for the effect of cyclo- Relative dose intensity Figure 2 Partial regression plot for relative median survival vs relative dose intensity. Plot represents the increase in median survival for a change in dose intensity within any given study. Vertical axis is on a log scale. Table III may be partly explained by the particular studies that were included in each analysis. The study effect was large in all the analyses (P<0.0001). Vertical axis is on a log scale.
The importance of cumulative dose of planned therapy has been suggested (Richardson et al., 1985; Geller et al., 1990) in breast cancer and the role of dose rate have been emphasised in several neoplasms (Levin & Hryniuk, 1987a; Meyer et al., 1991; Lasa et al., 1991) . In ovarian cancer the findings suggested a strong relationship between dose intensity and survival. However these results have been criticised because of the possibility of biases, especially the possibility that better prognosis patients are selected for trials that employ more intensive regimens and that publication bias favours the reporting of small non-randomised trials of aggres sive regimens that result in spuriously high response rates.
Our study tried to overcome some of these potential biases.
We restricted attention to randomised trials and avoided comparing patients in one trial with those in another trial: comparison is made only within each trial because the model (Gelman, 1990; Gelman & Neuberg, 1991 (Begg & Berlin, 1989) , which could be further accentuated by the fact that only between half and two-thirds of the published studies had enough data for inclusion in this study. Secondly, median survival may not be the most sensitive endpoint for measuring the impact of dose intensity. Unfortunately, long term survival, perhaps a more sensitive endpoint, was not available in many studies. Moreover, it was not possible to evaluate the effect of the subsequent management on survival. This could partially account for the less impressive relationship between doseintensity and survival compared to dose-intensity and response. Patients failing first-line non-platinum chemotherapy are more likely to respond to second-line treatment with platinum than are patients failing first-line platinum who receive other second-line treatments including second-line platinum. This observation has been used to partially explain the lack of survival benefit in randomised trials comparing platinum compounds with a single alkylating agent (Advanced Ovarian Cancer Trialist Group, 1991) . Thirdly, we can estimate the relationship between a specified increase in total dose intensity and outcome (response and survival), but we cannot really estimate the shape of the relationship. Our estimates were based on the assumption of linearity, but the data were not sufficient to distinguish different shapes while controlling for study differences. Nevertheless, the results presented here confirm that there is a relationship between overall dose intensity and response or survival after adjusting for study effects. For survival, this relationship seems smaller than the one found by Levin and Hryniuk (1987a) . The units of dose intensity for individual drugs are defined by Table I1 and an increase in relative dose intensity of two units generally is accompanied by a major increase in serious or life threatening toxicities. It also has to be considered that there were few studies in which arms differed by more than one unit of total dose-intensity, and, consequently, it is not possible to make any comment on whether the relationship between outcome and dose-intensity continue beyond that range. This less optimistic result concerning dose-intensity and survival is in better agreement with the disappointing situations in advanced disease, but also indicates that the development of effective toxicity reduction agents would be of benefit in this chemosensitive neoplasm. The fact that the regression coefficients for survival are about the same for cisplatin and doxorubicin confirms the importance of using these drugs at an intensive rate. In addition, these results confirm the role of cisplatin in advanced ovarian carcinoma, in agreement with the AOCTG meta-analysis (Advanced Ovarian Cancer Trialist Group, 1991) . They also underline the important role of doxorubicin, helping in the interpretation of the finding of a recent metaanalysis (Ovarian Cancer Meta-Analysis Project, 1991) , which showed a superiority of a CAP over a CP regimen.
In summary, the validity of the dose intensity hypothesis in advanced ovarian cancer is substantiated based on the utilisation of improved methodology for analysis of available data. This approach suggests hypotheses for the intensification of therapy and reinforces the importance of formally evaluating dose intense regimens in prospective randomised clinical trials.
